Palomar to Host PaloVia Skin Renewing Laser Analyst and Investor Meeting in NYC
January 06 2011 - 8:00AM
Palomar Medical Technologies, Inc. (Nasdaq:PMTI), a leading
researcher and developer of light-based systems for cosmetic
treatments, will host an analyst and investor meeting to discuss
its launch plans for the first FDA-cleared, at-home laser
clinically proven to reduce fine lines and wrinkles around the eyes
- the PaloVia™ Skin Renewing Laser™. The meeting will be held today
from 10AM to 12PM in New York City at the Nasdaq MarketSite, 4
Times Square, second floor Press Conference Room. Presenters
from Palomar will be Joseph Caruso, Chief Executive Officer; Paul
Weiner, Chief Financial Officer; Nancy Teumer, Global Marketing
Director Consumer Products; David Montgomery, Consumer Products
Sales Director; and Richard Bankowski, Field Clinical Director and
QVC Spokesperson. Also presenting will be Palomar's PaloVia
Expert Panel member, Dr. Robert Weiss, Director, Maryland Laser,
Skin & Vein Institute. Attendees are asked to arrive early
to allow adequate time for security checks. For analysts and
investors that are not able to attend the PaloVia launch meeting in
New York City, the meeting will also be accessible via webcast in
the About Palomar/Investors section of Palomar's website at
palomarmedical.com.
About Palomar Medical Technologies, Inc.:
Palomar Medical Technologies (Nasdaq:PMTI) designs, produces and
sells the most advanced cosmetic lasers and intense pulsed light
(IPL) systems to dramatically improve the appearance of women's and
men's skin. For over 15 years, Palomar has pioneered the
science of using lasers and light to improve appearances. As the
industry's technology leader, Palomar has invested in creating
cosmetic laser and IPL systems that put real value in the hands of
physicians and other professionals to benefit
consumers. Thousands of physicians worldwide trust and depend
on Palomar technology to not only introduce new aesthetic
treatments such as advanced laser hair removal, laser liposuction,
skin resurfacing, acne, laser treatments for scars, wrinkle
treatment, stretch marks (striae), and photofacials for pigmented
and vascular lesions, but to also make them robust, faster, more
powerful, and more comfortable for those being treated. In
June 2009, Palomar became the first company to receive a 510(k)
over-the-counter ("OTC") clearance from the FDA for a new,
patented, home-use, laser device for the treatment of fine lines
and wrinkles around the eyes (periorbital wrinkles). OTC clearance
allows these products to be marketed and sold directly to consumers
without a prescription.
For more information on Palomar and its professional products,
visit the company's website at palomarmedical.com. To continue
receiving the most up-to-date information and latest news on
Palomar as it happens, sign up to receive automatic e-mail alerts
by going to the About Palomar/Investors section of the website.
For more information on PaloVia, visit the PaloVia website at
palovia.com.
CONTACT: Palomar Medical Technologies, Inc.
Investor/Financial Contact:
Kerry McAnistan, Investor Relations Assistant
781-993-2411
ir@palomarmedical.com
Bratskeir & Company
Consumer Media Contact:
Lauren Glicken O'Leary
lgoleary@bratskeir.com
Rebecca Levitt
rlevitt@bratskeir.com
212-679-2233
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
Historical Stock Chart
From Jul 2023 to Jul 2024